Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Autogel plus temozolomide in progressive well-differentiated thoracic neuroendocrine tumors
2014-005579-10Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jan 2019
- Modality
- Peptides, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lanreotide and temozolomide in thoracic neuroendocrine tumor, Bronchopulmonary Carcinoid (BPC) and thymic carcinoid tumor, sponsored by Ipsen. Primary endpoint: Disease control rate at 9 months. Started Jan 2019; status: completed.
02
Drugs
lanreotidetemozolomide
03
Conditions
thoracic neuroendocrine tumorBronchopulmonary Carcinoid (BPC)thymic carcinoid tumor
Beyond the preview
Go deeper on 2014-005579-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005579-10.